Recently, the Beijing Intellectual Property Court issued a judgment in the administrative dispute over invention patent invalidation between a Chongqing Biotechnology Co., Ltd. (plaintiff), the National Intellectual Property Administration (defendant), and Denka Company Limited (third party). The Court dismissed the plaintiff's claims and confirmed the full validity of Denka Company Limited's Chinese invention patent No. 201410058250.0, titled "Method and Kit for Quantitative Determination of Small, Dense LDL Cholesterol" (hereinafter referred to as the "sdLDL Cholesterol Assay Patent").

In July 2022, the Beijing Intellectual Property Court issued a judgment in the corresponding infringement case of the aforementioned patent, ruling that the defendant Chongqing Biotechnology Co., Ltd. constituted infringement. The defendant was ordered to cease manufacturing, selling, and offering for sale the infringing products, and to compensate Denka Company Limited a total of RMB 3.5 million for economic losses and reasonable expenses incurred in enforcing its rights. Beijing Caihe Law Firm was entrusted by Denka Company Limited to act as its agent in the invalidation proceedings, administrative litigation proceedings, and infringement litigation proceedings.